Secondly, AMPs have been established to have substantial lytic action against multi-drug resistant cancer cells, and lastly AMP anticancer agents are resistant against urine and serum proteolysis due to their biochemical structures, thus making them perfect candidates for the management of intravesical tumor [78]. This evidence concerns the gene ADSL and cancer.